Expert NetworkExpert InterviewALLO

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing Allogene Therapeutics' Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma

Executed on:Apr 29, 2026 4:00 PM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: South Nassau Oncology
  • Senior Partner of South Nassau Oncology, Professor of Medicine at the Mount Sinai Hospital and Former Director of the Cancer Program at the Mount Sinai Hospital
  • Manages 150 patients with large B-cell lymphoma, 25+ with NSCLC and 80 patients with AML
  • Clinical focus on hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma and leukemias; as well as cancers of the lung, colon and breast.

Interview Goal

To gain a deeper understanding of Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.